Epcoritamab: Clinical Trials

6 trials of Epcoritamab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 active not recruiting. 6 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 36Active not recruiting 6

Follow Epcoritamab: new trials by email Literature Review of Epcoritamab trials Research Report on Epcoritamab

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Epcoritamab, Rituximab, Lenalidomide - Diffuse Large B-Cell Lymphoma
Phase 3Active not recruitingGenmab3792024-08-132026-04-08
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Epcoritamab, Prednisone, Rituximab - Follicular Lymphoma (FL)
Phase 3Active not recruitingGenmab10952024-02-052026-08-04
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Epcoritamab, Cyclophosphamide, Rituximab - Diffuse Large B-Cell Lymphoma
Phase 3Active not recruitingGenmab9002023-02-082026-09-11
A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China
Epcoritamab, Investigator's Choice Chemotherapy - Diffuse Large B-Cell Lymphoma
Phase 3Active not recruitingGenmab722022-10-082026-11-10
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
Epcoritamab, Rituximab, Lenalidomide - Follicular Lymphoma (FL)
Phase 3Active not recruitingGenmab5492022-09-202026-07-08
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Epcoritamab, Investigator's Choice Chemotherapy - Diffuse Large B-cell Lymphoma
Phase 3Active not recruitingGenmab4832021-01-132026-11-03

Conditions studied

Lymphoma, Large B-Cell, Diffuse (4)  ·  Lymphoma, Non-Hodgkin (3)  ·  Neoplasms (3)  ·  Lymphoma (2)  ·  Lymphoma, Follicular (2)  ·  Recurrence (1)

Sponsors

Genmab (6)

Countries

Australia (5)  ·  Belgium (5)  ·  Canada (5)  ·  China (5)  ·  France (5)  ·  Hungary (5)  ·  Japan (5)  ·  Netherlands (5)  ·  Poland (5)  ·  South Korea (5)  ·  Taiwan (5)  ·  Turkey (Türkiye) (5)  ·  United Kingdom (5)  ·  United States (5)  ·  Brazil (4)

Results publications

PMID 41371238

NIH funding

2023 (4)